• <abbr id="ck0wi"><source id="ck0wi"></source></abbr>
    <li id="ck0wi"></li>
  • <li id="ck0wi"><dl id="ck0wi"></dl></li><button id="ck0wi"><input id="ck0wi"></input></button>
  • <abbr id="ck0wi"></abbr>
  • <li id="ck0wi"><dl id="ck0wi"></dl></li>
  • Home >

    Hope Of Patients With Rare Diseases Under "No Medicine" And "High Price Medicine": Multi Payment Assistance Program

    2020/8/26 11:32:00 0

    SkyrocketingRare DiseasePatientHopeAidPlan

    "No medicine" and "can't afford" have become the biggest obstacle for patients with rare diseases to seek medical treatment. This is a special medicine for spinal cord atrophy.

    In this regard, at the second rare disease cooperation and exchange meeting recently, Zhang Wenbao, director of the medical administration bureau of the National Health Commission, pointed out that the prevention and control of rare diseases involves the construction of hierarchical diagnosis and treatment system, the construction of drug supply security system, and the reform of medical insurance payment mode. The steady promotion of rare disease prevention and control involves a wide range of aspects, and requires the full cooperation of multiple government departments and social forces.

    Wu Xiaobin, general manager and President of Baiji Shenzhou China region, pointed out to the 21st century economic reporter that the most important thing in medicine is policy. As long as the policy is right, there will be no problem in the development of rare disease medicine in China, such as simplifying the examination and approval, simplifying the process, and medical insurance can quickly keep up with it. Professor Shi Luwen, director of the International Research Center for medical management of Peking University, pointed out that in terms of medical security, the mode of government guidance, multi-party participation and third-party win-win situation, or the system that China must find ways to build in the future.

    Wang yiou, Secretary General of the Beijing pain challenge foundation, also pointed out to the 21st century economic reporter that the challenges faced by patients with rare diseases involve many aspects, which are extremely complex and can not be solved by any party alone. "The research, diagnosis and treatment of rare diseases, payment and guarantee of treatment expenses for rare diseases, research and development, clinical and admittance of related drugs, genetic inheritance and fertility of rare diseases, social support systems such as psychology, education and employment of patients, and cognition of rare diseases in the whole society are all common problems faced by rare disease groups."

    It is difficult to use drugs in patients with rare diseases

    "The vast majority of patients with rare diseases have been misdiagnosed on their way to medical treatment, because the disease is too few, so the doctors do not know, and it is difficult to make a diagnosis. 99% of them have no medicine; 1% of them have medicine, which is foreign medicine, but not in China, so they can't get in. It's not easy for us to come in and it's too expensive to buy without medical insurance." These are not easy to describe the difficult road of seeking medical treatment for patients with rare diseases.

    If the special effect of mucopolysaccharide was introduced into the market in China in 2020, she would have told her that polysaccharide would have been used for the diagnosis and treatment of mucopolysaccharide type I in the 21st century.

    "I've been waiting for this medicine for 17 years, and there's no medicine during this period. Now I've got skeletal deformity, corneal opacity and other symptoms. On June 3, the State Drug Administration approved the listing of aierzan through the priority review and approval process. I hope the price can be more friendly in the future. " Zhang Xiao pointed out.

    Not long ago, Wu Shiping, a 32 year old citizen in Huaihua City, Hunan Province, also asked for help on the Internet. His son, who is more than one year old, suffers from spinal muscular atrophy and has been lying in the ICU of the hospital for several months. He is in urgent need of an injection of a specific drug called nosinasheng sodium, which costs about 700000 yuan per injection.

    In fact, high drug price has become a big problem for patients.

    According to statistics, about 7000 rare diseases have been confirmed worldwide. According to the definition given by the genetics branch of the Chinese Medical Association, rare diseases are diseases or diseases with a prevalence of less than one in 500000 or a neonatal incidence of less than one in ten thousand. According to this estimate, there are more than 20 million patients with rare diseases in China. Many of them are from childhood, and their conditions are often serious.

    According to the China rare disease drug accessibility report (2019), 42% of the patients did not receive any treatment from 2014 to 2018, while the vast majority of the patients who received treatment failed to take the treatment drugs timely and adequately; more than half of the patients were disabled due to illness, of which 29% were physically disabled, 15% were multiple disabilities (i.e., there were more than two types of disability at the same time); 80% of the patients were disabled due to diseases The annual family income of patients is less than 50000 yuan, and more than half of the patients spend 80% of the annual family income on disease treatment, which is far beyond the 40% safety threshold defined by the World Health Organization.

    Due to the high price of rare diseases, Du Xiangyang, chief analyst of Southwest Securities pharmaceutical, said that the number of patients with a single rare disease is small, so the number of patients suitable for the drug is small, and the market demand for a single disease is low. However, at present, the research and development costs of innovative drugs are high, so it is difficult for enterprises to recover the R & D costs, which has hit the enthusiasm of enterprises in R & D to a certain extent.

    In addition to economic pressure, patients with rare diseases also face mental pressure. For example, a person in charge of aixike, a public welfare organization for pulmonary hypertension, told the reporter of the 21st century economic report: "patients with pulmonary hypertension are a kind of pulmonary vascular disease with a high degree of malignancy and can not be cured at present. Dyspnea, shortness of breath, suffocation and hemoptysis are common symptoms. With the continuous increase of pulmonary vascular resistance in patients, heart and respiratory failure can eventually be caused These patients usually do not have particularly significant symptoms. Except for the blue lips, the symptoms are "recessive". They are often misunderstood as lazy when they are working, and they are also rejected when applying for the minimum living allowance

    Multi party co payment scheme launched

    According to Wang yiou, the challenges faced by patients with rare diseases include research, diagnosis and treatment of rare diseases, payment and guarantee of treatment expenses for rare diseases, research and development, clinical and admission of related drugs, genetic inheritance and fertility of rare diseases, social support systems such as psychology, education and employment of patients, and cognition of rare diseases in the whole society All these problems need to be solved together.

    Zhang Wenbao pointed out that in view of rare diseases, one is to focus on prevention, and most of them are congenital and genetic diseases. Through premarital examination, prenatal examination and neonatal disease screening, we can reduce the occurrence of birth defects and reduce the long-term health damage caused by diseases to newborns; the second is to implement classified measures. The third is to steadily promote the prevention and treatment of rare diseases, involving a wide range of government departments and social forces to work together.

    At present, in order to solve the core problem of drug use and payment, the government, pharmaceutical enterprises and charitable organizations are also making joint efforts.

    In order to help patients with rare diseases solve their medication problems, for example, relevant departments have successively issued regulations and implementation measures in respect of VAT reduction, special examination and approval, special channels, priority review, and acceleration of listing, which greatly accelerated the speed of foreign rare disease drugs entering China and benefiting Chinese patients.

    In terms of payment, national health care administrators are also trying to include high-priced drugs in the health insurance list through negotiation. In 2017, the Ministry of human resources and social security for the first time included two orphan drugs (recombinant human coagulation factor VIIa for hemophilia and recombinant human interferon beta 1b for multiple sclerosis) into the medical insurance list through the national negotiation mechanism. In 2018, the State Council's institutional reform established the National Medical Security Bureau, which is responsible for the management of medical insurance. In 2019, the national medical insurance catalogue operated by the National Health Insurance Bureau was updated, and rare disease drugs were included for the first time.

    However, the payment of rare diseases can not only rely on national health insurance.

    On July 31, the State Medical Insurance Bureau deliberated and promulgated the "Interim Measures for the administration of drug use in basic medical insurance". Article 4 of the Interim Measures points out that we should adhere to the functional orientation of "basic medical insurance", do our best and do what we can, and the level of medication security should be compatible with the basic medical insurance fund and the affordability of the insured.

    Professor Shi Luwen pointed out that in terms of medical security, the mode of government guidance, multi-party participation and third-party win-win, or the system that China must find ways to build in the future.

    Wang yiou put forward the concept of "value co creation", that is, patients, doctors, government, enterprises and other parties can explore different modes, and there are different leading parties in different modes. We should promote all relevant parties to participate in and work together to find the best way to overcome rare diseases or coexist peacefully with rare diseases, seek the maximization of patients' health, and finally share the benefits What we have achieved.

    "As a charity, we can make suggestions from the perspective of social philanthropy, together with the support of enterprises, commercial insurance and medical insurance policies, so as to reduce the burden of patients more effectively." Wang further explained that this multi-party co payment model has been recognized by the local government.

    "In accordance with this idea, we launched two local special pilot projects in Zhejiang and Shanxi in the first half of this year, and have started to receive assistance applications from local patients. Through the multi-party co payment model, the pressure of the government is reduced, and the confidence of patients' families is improved. In the second half of the year, we will continue to promote the medical assistance project for rare diseases to more regions, and such a project is a typical development resource model. That is to say, patients' organizations should take the lead and participate in creating new methods conducive to problem-solving, which can promote the whole problem to be better solved. " Wang yiou said.

    At the same time, Wu Xiaobin pointed out to the 21st century economic reporter that if there is national policy support, enterprises are also willing to participate. "Every country has a special policy for rare diseases, because the number of rare patients is very small, and the research and development cost, time and investment are very large. If there are special policies, such as simplifying the approval and simplifying the process, the medical insurance can quickly keep up with it, and we will have the motivation to research and develop again. It is hoped that the policy can be improved as soon as possible to better support the research and development of drugs for rare diseases in China. "

    ?

    • Related reading

    Jicai Failed To Select The Original Pharmaceutical Factory To Survive And Transform Into An Off Hospital Drugstore Market

    Professional market
    |
    2020/8/26 11:32:00
    0

    Zheng Mian Seizes The Opportunity Of Reverse Operation

    Professional market
    |
    2020/8/25 14:47:00
    164

    Jingdong Logistics Jointly Released The First White Paper On Digital Twin Supply Chain In The Industry

    Professional market
    |
    2020/8/19 10:11:00
    0

    Volume Growth Of China'S Light And Cotton Fabrics In Autumn

    Professional market
    |
    2020/8/19 9:27:00
    183

    Under The Direct Marketing Trend Behind The Flow Marketing Of "Tesla Group Purchase", Is The Auto E-Commerce False Proposition?

    Professional market
    |
    2020/8/19 9:24:00
    12
    Read the next article

    Jicai Failed To Select The Original Pharmaceutical Factory To Survive And Transform Into An Off Hospital Drugstore Market

    With the expansion of purchasing with quantity, the price and profit of generic drugs return reasonably. In the future, the ability of cost control and supply chain management will become the main competition of pharmacies in the future

    主站蜘蛛池模板: 欧美另类videosgratis妇| 99热在线精品播放| 色爱无码av综合区| 日本高清免费不卡在线播放| 国产熟女一区二区三区五月婷| 亚洲国产精品自产在线播放| 91福利在线观看视频| 欧美黑人疯狂性受xxxxx喷水| 在线观看网站禁入口不用下载| 人妻少妇精品视频一区二区三区| 一级做a爰片久久免费| 精品国产一区二区三区香蕉 | 性欧美激情videos| 欧美性猛交xxxx乱大交蜜桃| 国产精品第44页| 国产成人小视频| 久久香蕉国产线看观看精品yw| 成年人在线看片| 日本电影痴汉电车| 国产九九久久99精品影院| 久久99国产精品久久99| 美女邪恶色动图gig27报| 成人中文字幕一区二区三区| 免费看黄视频app| 99久久国产视频| 欧美午夜一区二区福利视频| 国产福利在线导航| 久久天天躁狠狠躁夜夜AV浪潮| 色欲香天天天综合网站| 成人18免费网站在线观看| 免费久久精品国产片香蕉| 999在线视频精品免费播放观看 | 亚洲AV无码成人黄网站在线观看| 黑人巨大精品欧美一区二区免费 | 国产超碰人人模人人爽人人喊| 亚洲国产香蕉碰碰人人| 国产男人午夜视频在线观看| 日本一道综合久久aⅴ免费 | 好紧我太爽了视频免费国产| 交性大片欧美网| jizz.日本|